Precigen, Inc. ( PGEN) Q3 2025 Earnings Call November 13, 2025 4:30 PM EST Good afternoon, ladies and gentlemen, and welcome to the Precigen Third Quarter 2025 Financial Results and Business Update ...

Papcemias FDA Approval -- Granted full FDA approval in August with the first and only available treatment for all adults with recurrent respiratory papillomatosis (RRP); label is broad with no ...

Disc Medicine will be enrolling 24 adults with SCD in its newly launched trial testing DISC-3405 at three doses for easing ...

The MarketWatch News Department was not involved in the creation of this content.-- New data from cohort 3 show EO2463 can be safely added to rituximab in first-line low-tumor-bur ...

General and Administrative (G&A) expenses: G&A expenses totaled $5.4 million for the third quarter ended September 30, 2025, compared to $1.4 million for the quarter ended September 30, 2024. G&A ...

It’s hard to think of vaccination without associating it with a sharp jab in the arm. But there are other, more gentle ways of activating the immune system, such as administering vaccines via the nose ...

Delcath Systems, Inc. , ("Delcath" or the "Company") an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced the publication of results ...